Influence of polymer molecular weight on in vitro dissolution behavior and in vivo performance of celecoxib:PVP amorphous solid dispersions

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 101, Issue , 2016, Pages 145-151

  Knopp, Matthias Manne ^a,b   Nguyen, Julia Hoang ^a,c   Becker, Christian ^b   Francke, Nadine Monika ^b   Jørgensen, Erling B ^a   Holm, Per ^a   Holm, René ^a,c   Mu, Huiling ^c   Rades, Thomas ^c   Langguth, Peter ^b  

^a H LUNDBECK A S   (Denmark)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Amorphous solid dispersion; Celecoxib; In vitro; In vivo; IVIVC; Molecular weight; Non sink dissolution; PVP

Indexed keywords

CELECOXIB; POVIDONE; POLYMER;

AMORPHOUS SOLID DISPERSION; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CRYSTALLIZATION; DISPERSION; DRUG BIOAVAILABILITY; DRUG RELEASE; DRUG SOLUBILITY; IN VITRO STUDY; MAXIMUM PLASMA CONCENTRATION; MOLECULAR WEIGHT; NONHUMAN; PARTICLE SIZE; PLASMA CONCENTRATION-TIME CURVE; RAT; SOLID; SOLID STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; BIOAVAILABILITY; CHEMISTRY; MALE; MEDICINAL CHEMISTRY; PROCEDURES; SOLUBILITY; SPRAGUE DAWLEY RAT;

ANIMALS; BIOLOGICAL AVAILABILITY; CELECOXIB; CHEMISTRY, PHARMACEUTICAL; CRYSTALLIZATION; MALE; MOLECULAR WEIGHT; POLYMERS; POVIDONE; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY;

EID: 84958972505     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2016.02.007     Document Type: Article

References (51)

1. S.V. Sastry, J.R. Nyshadham, and J.A. Fix Recent technological advances in oral drug delivery - a review Pharm. Sci. Technol. Today 3 2000 138 145
2. S. Mignani, K.S. El, M. Bousmina, and J.P. Majoral Expand classical drug administration ways by emerging routes using dendrimer drug delivery systems: a concise overview Adv. Drug Deliv. Rev. 65 2013 1316 1330
3. C.A. Lipinski Drug-like properties and the causes of poor solubility and poor permeability J. Pharmacol. Toxicol. 44 2000 235 249
4. C.W. Pouton Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system Eur. J. Pharm. Sci. 29 2006 278 287
5. S. Gupta, R. Kesarla, and A. Omri Formulation strategies to improve the bioavailability of poorly absorbed drugs with special emphasis on self-emulsifying systems ISRN Pharm. 2013 2013 848043
6. G.L. Amidon, H. Lennernas, V.P. Shah, and J.R. Crison A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability Pharm. Res. 12 1995 413 420
7. D. Hörter, and J.B. Dressman Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract Adv. Drug Deliv. Rev. 46 2001 75 87
8. A. Fahr, and X. Liu Drug delivery strategies for poorly water-soluble drugs Expert Opin. Drug Deliv. 4 2007 403 416
9. S. Stegemann, F. Leveiller, D. Franchi, J.H. de, and H. Linden When poor solubility becomes an issue: from early stage to proof of concept Eur. J. Pharm. Sci. 31 2007 249 261
10. J. Brouwers, M.E. Brewster, and P. Augustijns Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability? J. Pharm. Sci. 98 2009 2549 2572
11. P. Gao, and Y. Shi Characterization of supersaturatable formulations for improved absorption of poorly soluble drugs AAPS J. 14 2012 703 713
12. T. Vasconcelos, B. Sarmento, and P. Costa Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs Drug Discov. Today 12 2007 1068 1075
13. D.Q. Craig The mechanisms of drug release from solid dispersions in water-soluble polymers Int. J. Pharm. 231 2002 131 144
14. C. Leuner, and J. Dressman Improving drug solubility for oral delivery using solid dispersions Eur. J. Pharm. Biopharm. 50 2000 47 60
15. P. Gupta, R. Thilagavathi, A.K. Chakraborti, and A.K. Bansal Role of molecular interaction in stability of celecoxib-PVP amorphous systems Mol. Pharm. 2 2005 384 391
16. H.R. Guzman, M. Tawa, Z. Zhang, P. Ratanabanangkoon, P. Shaw, C.R. Gardner, H. Chen, J.P. Moreau, O. Almarsson, and J.F. Remenar Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations J. Pharm. Sci. 96 2007 2686 2702
17. S. Sethia, and E. Squillante Solid dispersion of carbamazepine in PVP K30 by conventional solvent evaporation and supercritical methods Int. J. Pharm. 272 2004 1 10
18. J. Breitenbach Melt extrusion: from process to drug delivery technology Eur. J. Pharm. Biopharm. 54 2002 107 117
19. S. Torrado, S. Torrado, J.J. Torrado, and R. Cadorniga Preparation, dissolution and chracterization of albendazole solid dispersions Int. J. Pharm. 140 1996 247 250
20. G. Van den Mooter, P. Augustijns, and R. Kinget Physico-chemical characterization of solid dispersions of temazepam with polyethyl glycol 6000 and PVP K30 Int. J. Pharm. 164 1998 67 80
21. K.J. Crowley, and G. Zografi The effect of low concentrations of molecularly dispersed poly(vinylpyrrolidone) on indomethacin crystallization from the amorphous state Pharm. Res. 20 2003 1417 1422
22. N.S. Trasi, K.A. Oucherif, J.D. Litster, and L.S. Taylor Evaluating the influence of polymers on nucleation and growth in supersaturated solutions of acetaminophen Cryst. Eng. Comm. 17 2015 1242 1248
23. A.P. Simonelli, S.C. Mehta, and W.I. Higuchi Dissolution rates of high energy polyvinylpyrrolidone (PVP)-sulfathiazole coprecipitates J. Pharm. Sci. 58 1969 538 549
24. H. Sekikawa, M. Nakano, and T. Arita Inhibitory effect of polyvinylpyrrolidone on the crystallization of drugs Chem. Pharm. Bull. 26 1978 118 126
25. R. Jachowicz Dissolution rates of partially water-soluble drugs from solid dispersion systems. II. Phenytoin Int. J. Pharm. 35 1987 7 12
26. J.E. Hilton, and M.P. Summers The effect of wetting agents on the dissolution of indomethacin solid dispersion systems Int. J. Pharm. 31 1986 157 164
27. D.E. Alonzo, G.G. Zhang, D. Zhou, Y. Gao, and L.S. Taylor Understanding the behavior of amorphous pharmaceutical systems during dissolution Pharm. Res. 27 2010 608 618
28. J. Anwar, P.K. Boateng, R. Tamaki, and S. Odedra Mode of action and design rules for additives that modulate crystal nucleation Angew. Chem. Int. Ed. Engl. 48 2009 1596 1600
29. J.L. Cohen, B.B. Hubert, L.J. Leeson, C.T. Rhodes, J.R. Robinson, T.J. Roseman, and E. Shefter The development of USP dissolution and drug release standards Pharm. Res. 7 1990 983 987
30. P. Augustijns, and M.E. Brewster Supersaturating drug delivery systems: fast is not necessarily good enough J. Pharm. Sci. 101 2012 7 9
31. A. Newman, G. Knipp, and G. Zografi Assessing the performance of amorphous solid dispersions J. Pharm. Sci. 101 2012 1355 1377
32. N.M. Davies, A.J. McLachlan, R.O. Day, and K.M. Williams Clinical pharmacokinetics and pharmacodynamics of celecoxib Clin. Pharmacokinet. 38 2000 225 242
33. S.K. Paulson, M.B. Vaughn, S.M. Jessen, Y. Lawal, C.J. Gresk, B. Yan, T.J. Maziasz, C.S. Cook, and A. Karim Pharmacokinetics of celecoxib after oral administration in dogs and humans: effect of food and site of absorption J. Pharmacol. Exp. Ther. 297 2001 638 645
34. N. Subramanian, S. Ray, S.K. Ghosal, R. Bhadra, and S.P. Moulik Formulation design of self-microemulsifying drug delivery systems for improved oral bioavailability of celecoxib Biol. Pharm. Bull. 27 2004 1993 1999
35. Y. Tsume, D.M. Mudie, P. Langguth, G.E. Amidon, and G.L. Amidon The Biopharmaceutics Classification System: subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC Eur. J. Pharm. Sci. 57 2014 152 163
36. G. Chawla, P. Gupta, R. Thilagavathi, A.K. Chakraborti, and A.K. Bansal Characterization of solid-state forms of celecoxib Eur. J. Pharm. Sci. 20 2003 305 317
37. Y. Shono, E. Jantratid, N. Janssen, F. Kesisoglou, Y. Mao, M. Vertzoni, C. Reppas, and J.B. Dressman Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling Eur. J. Pharm. Biopharm. 73 2009 107 114
38. M.S. Nagarsenker, and M.S. Joshi Celecoxib-cyclodextrin systems: characterization and evaluation of in vitro and in vivo advantage Drug Dev. Ind. Pharm. 31 2005 169 178
39. G.P. Andrews, O. Abu-Diak, F. Kusmanto, P. Hornsby, Z. Hui, and D.S. Jones Physicochemical characterization and drug-release properties of celecoxib hot-melt extruded glass solutions J. Pharm. Pharmacol. 62 2010 1580 1590
40. P. Gupta, V.K. Kakumanu, and A.K. Bansal Stability and solubility of celecoxib-PVP amorphous dispersions: a molecular perspective Pharm. Res. 21 2004 1762 1769
41. M.M. Knopp, J.H. Nguyen, H. Mu, P. Langguth, T. Rades, and R. Holm Influence of Copolymer Composition on In Vitro and In Vivo Performance of Celecoxib-PVP/VA Amorphous Solid Dispersions AAPS J. 2016 10.1208/s12248-016-9865-6
42. M. Sovizi Thermal behavior of drugs: investigation on decomposition kinetic of naproxen and celecoxib J. Therm. Anal. Calorim. 102 2010 285 289
43. M.F. Silva, C.A. Da Silva, F.C. Fogo, E.A.G. Pineda, and A.A. Hechenleitner Thermal and FTIR study of polyvinylpyrrolidone/lignin blends J. Therm. Anal. Calorim. 79 2005 367 370
44. J.H. Lee, M.J. Kim, H. Yoon, C.R. Shim, H.A. Ko, S.A. Cho, D. Lee, and G. Khang Enhanced dissolution rate of celecoxib using PVP and/or HPMC-based solid dispersions prepared by spray drying method J. Pharm. Invest. 43 2013 205 213
45. M.M. Knopp, N.E. Olesen, P. Holm, P. Langguth, R. Holm, and T. Rades Influence of polymer molecular weight on drug-polymer solubility: a comparison between experimentally determined solubility in PVP and prediction derived from solubility in monomer J. Pharm. Sci. 104 2015 2905 2912
46. K. Khougaz, and S.D. Clas Crystallization inhibition in solid dispersions of MK-0591 and poly(vinylpyrrolidone) polymers J. Pharm. Sci. 89 2000 1325 1334
47. S.L. Raghavan, A. Trividic, A.F. Davis, and J. Hadgraft Crystallization of hydrocortisone acetate: influence of polymers Int. J. Pharm. 212 2001 213 221
48. E. Sjögren, B. Abrahamsson, P. Augustijns, D. Becker, M.B. Bolger, M. Brewster, J. Brouwers, T. Flanagan, M. Harwood, C. Heinen, R. Holm, H.P. Juretschke, M. Kubbinga, A. Lindahl, V. Lukacova, U. Munster, S. Neuhoff, M.A. Nguyen, A. Peer, C. Reppas, A.R. Hodjegan, C. Tannergren, W. Weitschies, C. Wilson, P. Zane, H. Lennernas, and P. Langguth In vivo methods for drug absorption - comparative physiologies, model selection, correlations with in vitro methods (IVIVC), and applications for formulation/API/excipient characterization including food effects Eur. J. Pharm. Sci. 57 2014 99 151
49. P.A. Dickinson, R.R. Abu, L. Ashworth, R.A. Barker, W.M. Burke, C.M. Patterson, N. Stainforth, and M. Yasin An investigation into the utility of a multi-compartmental, dynamic, system of the upper gastrointestinal tract to support formulation development and establish bioequivalence of poorly soluble drugs AAPS J. 14 2012 196 205
50. J. Bevernage, J. Brouwers, P. Annaert, and P. Augustijns Drug precipitation-permeation interplay: supersaturation in an absorptive environment Eur. J. Pharm. Biopharm. 82 2012 424 428
51. D.E. Alonzo, S. Raina, D. Zhou, Y. Gao, G.G.Z. Zhang, and L.S. Taylor Characterizing the impact of hydroxypropylmethyl cellulose on the growth and nucleation kinetics of felodipine from supersaturated solutions Cryst. Growth Des. 12 2012 1538 1547